公开(公告)号：WO2015085398A1

公开(公告)日：2015-06-18

申请号：PCT/CA2014/000875

申请日：2014-12-09

Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCH ,  THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT

Inventor： JONES, Steven John Mathias ,  DARGAHI, Daryanaz ,  BABCOOK, John Stephen

IPC: C12N15/37 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P35/00 ,  C07K16/40 ,  C07K16/46 ,  C12N9/64 ,  C12Q1/68 ,  G01N33/48 ,  G01N33/574

CPC classification number: G01N33/57449 ,  C12N9/6421 ,  C12Q1/68 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N33/57415 ,  G01N33/57423 ,  G01N33/57434

Abstract: Described are variants of matriptase that are associated with cancer. The variants encode polypeptides that are missing all or part of an LDLRA1 domain and/or all or part of a LDLRA3 domain. Also described are binding agents such as antibodies that are selective for the variant matriptase polypeptides as well as conjugates thereof. The binding proteins and conjugates are useful for the identification of cancer cells or for the treatment of cancer.

Abstract translation: 描述了与癌症相关的matriptase的变体。 该变体编码缺失LDLRA1结构域和/或全部或部分LDLRA3结构域的全部或部分的多肽。 还描述了对变体matriptase多肽及其缀合物具有选择性的结合剂，例如抗体。 结合蛋白和结合物可用于鉴定癌细胞或治疗癌症。

公开(公告)号：WO2011083099A1

公开(公告)日：2011-07-14

申请号：PCT/EP2011/050004

申请日：2011-01-03

Applicant: F. HOFFMANN-LA ROCHE AG ,  BANNER, David ,  BENZ, Joerg ,  RUF, Armin ,  SCHLATTER, Daniel ,  STIHLE, Martine

Inventor： BANNER, David ,  BENZ, Joerg ,  RUF, Armin ,  SCHLATTER, Daniel ,  STIHLE, Martine

IPC: C12N9/64 ,  G01N33/68

CPC classification number: G01N33/573 ,  C07K2299/00 ,  C12N9/6421 ,  C12N9/6478 ,  C12Y304/23046 ,  G01N33/68

Abstract: The present invention relates to crystals of human β-secretase in apo-form and with an inhibitor, and to the three-dimensional X-ray crystal structure derived thereof.

Abstract translation: 本发明涉及载体形式和抑制剂的人β-分泌酶的晶体及其衍生的三维X射线晶体结构。

公开(公告)号：WO2009121948A2

公开(公告)日：2009-10-08

申请号：PCT/EP2009053985

申请日：2009-04-03

Applicant: VIB VZW ,  UNIV LEUVEN KATH ,  UNIV BRUXELLES ,  DE STROOPER BART ,  MARJAUX ELS ,  ZHOU LUJIA ,  MUYLDERMANS SERGE

Inventor： DE STROOPER BART ,  MARJAUX ELS ,  ZHOU LUJIA ,  MUYLDERMANS SERGE

IPC: C07K16/40 ,  C12N9/64 ,  G01N33/68

CPC classification number: C07K16/40 ,  C07K2317/22 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C12N9/6421

Abstract: The present invention relates to single domain antibodies with a specificity for BACE1. More specifically, the invention provides single variable domain antibodies derived from camelids which bind to BACE1 and are capable of inhibiting the activity of BACE1. Said antibodies can be used for research and medical applications. Specific applications include the use of BACE1 specific antibodies for the treatment of Alzheimer's disease.

Abstract translation: 本发明涉及对BACE1具有特异性的单结构域抗体。 更具体地，本发明提供了衍生自结合BACE1并能够抑制BACE1活性的骆驼类的单可变结构域抗体。 所述抗体可用于研究和医学应用。 具体应用包括使用BACE1特异性抗体治疗阿尔茨海默病。

公开(公告)号：WO2008121813A3

公开(公告)日：2009-02-05

申请号：PCT/US2008058648

申请日：2008-03-28

Applicant: GENENTECH INC ,  DIXIT VISHVA ,  KAYAGAKI NOBUHIKO

Inventor： DIXIT VISHVA ,  KAYAGAKI NOBUHIKO

IPC: A61K31/713 ,  C12N9/64 ,  C12N15/113

CPC classification number: A61K31/713 ,  C12N9/6421 ,  C12N15/1137 ,  C12N2310/14 ,  C12Y304/19012

Abstract: Methods of using DUBA polypeptides and nucleic acids in modulating cytokine production and in modulating immune response are provided. Methods of diagnosing and treating certain pathophysiological conditions using the DUBA polypeptides and nucleic acids of the invention are also provided.

Abstract translation: 提供了使用DUBA多肽和核酸调节细胞因子产生和调节免疫应答的方法。 还提供了使用本发明的DUBA多肽和核酸诊断和治疗某些病理生理条件的方法。

公开(公告)号：WO2008037930A3

公开(公告)日：2008-06-19

申请号：PCT/FR2007052023

申请日：2007-09-27

Applicant: BIOMERIEUX SA ,  UNIV RABELAIS FRANCOIS ,  AINCIBURU MIREILLE ,  COURTY YVES ,  JOLIVET-REYNAUD COLETTE ,  PLANQUE CHRIS

Inventor： AINCIBURU MIREILLE ,  COURTY YVES ,  JOLIVET-REYNAUD COLETTE ,  PLANQUE CHRIS

IPC: C12Q1/68

CPC classification number: C12N9/6421 ,  C12Q1/6886 ,  C12Q2600/118

Abstract: The invention relates to a method for the in vitro diagnosis of bronchial carcinoma, particularly non-small cell lung cancer, characterised in that it includes a step comprising the detection of at least one of the major alternative transcripts of the KLK8 gene encoding kallikrein 8 in a biological sample taken from a patient suspected of having bronchopulmonary carcinoma. Said method is particularly suitable for prognosticating survival in patients with bronchial carcinoma.

Abstract translation: 本发明涉及用于体外诊断支气管癌特别是非小细胞肺癌的方法，其特征在于它包括检测编码激肽释放酶8的KLK8基因的至少一种主要可选转录物的步骤 取自怀疑患有支气管肺癌的患者的生物样品。 所述方法特别适用于预测支气管癌患者的存活。

公开(公告)号：WO2007055979A2

公开(公告)日：2007-05-18

申请号：PCT/US2006/042527

申请日：2006-11-01

Applicant: MEYER PHARMACEUTICALS LLC ,  GATANAGA, Tetsuya ,  MEDRANO, Michael ,  NIECE, Ronald, L.

Inventor： GATANAGA, Tetsuya ,  MEDRANO, Michael ,  NIECE, Ronald, L.

CPC classification number: C12N9/6421 ,  A61K38/00 ,  C12N9/6489

Abstract: This disclosure provides a new family of proteins implicated in causing the release of TNF receptors and other cytokine receptors from the surface of cells involved in inflammation. Receptor releasing activity was isolated and purified from a monocyte cell line, and sequenced to deduce the gene and protein structure of several different metalloproteases. The information provided in this disclosure enables the user to prepare recombinant protein or expression vectors that will cause receptor release in vivo, thus preventing signal transduction and blocking the effect of incoming cytokines. Medicaments containing cytokine receptor releasing activity are described for use in treating rheumatoid arthritis and other conditions mediated by inflammatory cytokines. The proteins of this invention are all relatively small single-chain molecules, and are therefore easier to use and more cost-effective than other currently marketed biological anti-inflammatory agents.

Abstract translation: 本公开内容提供了一种新的家族蛋白质，其涉及从炎症参与的细胞表面释放TNF受体和其他细胞因子受体。 从单核细胞系分离和纯化受体释放活性，并测序以推断几种不同金属蛋白酶的基因和蛋白质结构。 本公开中提供的信息使得使用者能够制备将导致体内受体释放的重组蛋白或表达载体，从而防止信号转导并阻断进入的细胞因子的作用。 描述了含有细胞因子受体释放活性的药物用于治疗由炎性细胞因子介导的类风湿性关节炎和其他病症。 本发明的蛋白质都是相对较小的单链分子，因此比其它目前市售的生物抗炎剂更容易使用和更具成本效益。

公开(公告)号：WO2004053052A3

公开(公告)日：2006-08-03

申请号：PCT/BR0300189

申请日：2003-12-08

Applicant: CAMARGO ANTONIO ,  HAYASHI MIRIAN ,  PORTARO FERNANDA ,  GUERREIRO JULIANO

Inventor： CAMARGO ANTONIO ,  HAYASHI MIRIAN ,  PORTARO FERNANDA ,  GUERREIRO JULIANO

IPC: C12N9/64

CPC classification number: C12N9/6421

Abstract: This invention refers to a process for the determination of the primary structure of the mRNA coding for human endooligopeptidase A (hEOPA) and its protein sequence. In addition, the invention relates to a process for the determination of the structure of the hEOPA gene and the production of recombinant hEOPA. Furthermore, the invention relates to a process of generating antibodies against hEOPA in mice.

Abstract translation: 本发明涉及确定编码人内寡肽酶A（hEOPA）的mRNA及其蛋白质序列的一级结构的方法。 此外，本发明涉及确定hEOPA基因的结构和重组hEOPA的产生的方法。 此外，本发明涉及在小鼠中产生针对hEOPA的抗体的方法。

公开(公告)号：WO2006064007A1

公开(公告)日：2006-06-22

申请号：PCT/EP2005/056753

申请日：2005-12-13

Applicant: VIB vzw ,  K.U.LEUVEN RESEARCH AND DEVELOPMENT ,  DE STROOPER, Bart ,  DEJAEGERE, Tim ,  SERNEELS, Lutgarde

Inventor： DE STROOPER, Bart ,  DEJAEGERE, Tim ,  SERNEELS, Lutgarde

IPC: C12N15/00 ,  A01K67/027 ,  C12N15/85 ,  C12N5/10 ,  G01N33/50 ,  C12N9/64

CPC classification number: C12N15/8509 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/10 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0312 ,  A01K2267/0318 ,  C12N9/6421

Abstract: The current invention relates to the field of neurodevelopmental disorders and more particularly to the field of neuropsychiatric disorders. The invention provides non-human, transgenic animal models for said neurodevelopmental disorders such as schizophrenia, bipolar disorders, compulsive disorders and the like. The animals also have applications in the field of Alzheimer's Disease and other disorders in which -secretase activity has a role.

Abstract translation: 本发明涉及神经发育障碍的领域，更具体地涉及神经精神障碍领域。 本发明提供了用于神经发育障碍如精神分裂症，双相情感障碍，强迫症等的非人类，转基因动物模型。 这些动物在阿尔茨海默氏病和其他分泌酶活性具有作用的疾病中也有应用。

公开(公告)号：WO2004056962A3

公开(公告)日：2006-02-16

申请号：PCT/US0338314

申请日：2003-12-02

Applicant: SUNESIS PHARMACEUTICALS INC

Inventor： BALLINGER MARCUS

IPC: C12N9/64 ,  C12N9/00

CPC classification number: C12N9/6421

Abstract: The present invention is directed to engineered polypeptides having BACE activity. In certain embodiments, the polypeptides also comprise an engineered cleavage site. Also provided are polypeptides comprising a prodomain, an engineered cleavage site, and a protease domain; the polypeptides are properly folded and are cleaved at the engineered cleavage site in vitro, producing homogeneous preparations of purified protease having BACE activity. The invention further pertains to nucleic acids, expression vectors, and host cells comprising the expression vectors for making the engineered polypeptides.

公开(公告)号：WO2005123119A2

公开(公告)日：2005-12-29

申请号：PCT/US2005/020516

申请日：2005-06-10

Applicant: CATALYST BIOSCIENCES, INC. ,  THANOS, Christopher, D. ,  MADISON, Edwin, L.

Inventor： THANOS, Christopher, D. ,  MADISON, Edwin, L.

IPC: A61K38/48

CPC classification number: C12N9/6421 ,  A61K38/00 ,  C12N9/6494 ,  C12Y304/24011

Abstract: Administration of recombinant, truncated mammalian NEP or certain bacterial homologues of this protein is therapeutically effective in the treatment of inflammatory bowel disease.

Abstract translation: 重组，截短的哺乳动物NEP或该蛋白质的某些细菌同系物的施用在治疗炎症性肠病中是治疗有效的。